Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Not all reference samples are equal in single-cell transcriptomics of human kidney tissue.

JCI insight·2026
Same author

Deep profiling of lupus nephritis kidneys reveals dynamic changes in myeloid cells associated with disease progression.

Annals of the rheumatic diseases·2026
Same author

Engineering TCR-directed T-cells for the treatment of multiple myeloma.

Frontiers in immunology·2026
Same author

A population-scale atlas of blood and tissue in lupus nephritis.

bioRxiv : the preprint server for biology·2026
Same author

Cost-Effectiveness of Maintaining Higher Stem-Cell Collection Thresholds in the Chimeric Antigen Receptor T-Cell Era for Multiple Myeloma.

JCO clinical cancer informatics·2026
Same author

CO-STIMULATORY BLOCKADE PREVENTS INTRAGRAFT ACCRUAL OF CLASS-SWITCHED, ACTIVATED B CELLS DESPITE FAILING TO PREVENT T-CELL MEDIATED REJECTION.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: May 21, 2026

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates
09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

Targeting the ubiquitin+proteasome system in solid tumors.

James J Driscoll1, E Steve Woodle

  • 1Division of Hematology-Oncology, Department of Internal Medicine, The Vontz Center for Molecular Studies, University of Cincinnati, Cincinnati, OH 45267, USA.

Seminars in Hematology
|June 26, 2012
PubMed
Summary

The ubiquitin-proteasome system (UPS) is crucial for protein balance and cell health. Proteasome inhibitors show promise in treating cancers like multiple myeloma, but challenges remain for solid tumors.

More Related Videos

Comparative Strategies for Ubiquitination Detection in Mammalian Cell Lysates Using SMAD2/SMURF2 as a Model
09:00

Comparative Strategies for Ubiquitination Detection in Mammalian Cell Lysates Using SMAD2/SMURF2 as a Model

Published on: April 17, 2026

Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations
10:26

Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations

Published on: November 7, 2019

Related Experiment Videos

Last Updated: May 21, 2026

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates
09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

Comparative Strategies for Ubiquitination Detection in Mammalian Cell Lysates Using SMAD2/SMURF2 as a Model
09:00

Comparative Strategies for Ubiquitination Detection in Mammalian Cell Lysates Using SMAD2/SMURF2 as a Model

Published on: April 17, 2026

Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations
10:26

Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations

Published on: November 7, 2019

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Biochemistry

Background:

  • The ubiquitin-proteasome system (UPS) regulates protein homeostasis and cell viability.
  • The proteasome, the catalytic core of the UPS, is essential for targeted protein removal.
  • Proteasome inhibitors (PIs) have demonstrated efficacy in treating certain cancers, notably multiple myeloma (MM).

Purpose of the Study:

  • To review the role of the UPS in cancer biology and drug development.
  • To discuss the success of PIs in hematologic malignancies and challenges in solid tumors.
  • To explore emerging therapeutic targets within the UPS beyond proteasome inhibition.

Main Methods:

  • Literature review of UPS function and PI therapies.
  • Analysis of clinical responses to bortezomib in multiple myeloma.
  • Exploration of non-proteolytic proteasome functions and Ub-binding proteins as therapeutic targets.

Main Results:

  • Proteasome inhibitors like bortezomib are effective against multiple myeloma, establishing the UPS as a key cancer target.
  • Expansion of PI therapy to solid tumors has faced challenges.
  • New therapeutic avenues within the UPS are emerging, including non-proteolytic proteasome activities and Ub-binding proteins.

Conclusions:

  • The UPS is a validated target in cancer therapy, particularly for hematologic malignancies.
  • Further research into novel UPS-targeting strategies is needed for broader anticancer applications, especially in solid tumors.
  • Molecular-genetic approaches are vital for advancing UPS-based cancer drug development.